33324 Federal Register / Vol. 86, No. 119 / Thursday, June 24, 2021 / Notices 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: June 17, 2021. 

David W Freeman, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–13279 Filed 6–23–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Diabetes and 

Digestive and Kidney Diseases; Notice 

of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel; NIDDK U24 SEP. 

Date: July 9, 2021. 

Time: 1:00 p.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Bethesda, MD 20892. 

Contact Person: Xiaodu Guo, M.D., Ph.D., 

Scientific Review Officer, Review Branch, 

DEA, NIDDK, National Institutes of Health, 

Room 7023, 6707 Democracy Boulevard, 

Bethesda, MD 20892–5452, (301) 594–4719, 

guox@extra.niddk.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.847, Diabetes, 

Endocrinology and Metabolic Research; 

93.848, Digestive Diseases and Nutrition 

Research; 93.849, Kidney Diseases, Urology 

and Hematology Research, National Institutes 

of Health, HHS) 

Dated: June 14, 2021. 

David W Freeman, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–13340 Filed 6–23–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Mental Health; 

Notice of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Mental Health Special Emphasis Panel; 

Clinical Trials of Pharmacologic or Devicebased Interventions for Mental Disorders 

(R61, R33, U01). 

Date: July 14, 2021. 

Time: 1:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Telephone 

Conference Call). 

Contact Person: Jasenka Borzan, Ph.D., 

Scientific Review Officer, Division of 

Extramural Activities, National Institutes of 

Mental Health, 6001 Executive Blvd., 

Neuroscience Center, Room 6150, Bethesda, 

MD 20892, 301–435–1260, jasenka.borzan@

nih.gov. 

Name of Committee: National Institute of 

Mental Health Special Emphasis Panel; 

Social Drivers of Mental Illnesses in Low- & 

Middle-Income Countries: Mechanisms and 

Pathways of Interventions for Youth (R01). 

Date: July 15, 2021. 

Time: 11:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Telephone 

Conference Call). 

Contact Person: Rebecca Steiner Garcia, 

Ph.D., Scientific Review Officer, Division of 

Extramural Activities, National Institute of 

Mental Health, NIH, Neuroscience Center, 

6001 Executive Blvd., Room 6149, MSC 9608, 

Bethesda, MD 20892–9608, 301–443–4525, 

steinerr@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program No. 93.242, Mental Health Research 

Grants, National Institutes of Health, HHS) 

Dated: June 16, 2021. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–13338 Filed 6–23–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Notice To Announce Request for 

Information (RFI) Inviting Input on 

NIAAA’s 2022–2026 Strategic Plan 

Outline 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The National Institute on 

Alcohol Abuse and Alcoholism 

(NIAAA) is currently developing an 

updated strategic plan to highlight 

priorities and guide activities for 

advancing the Institute’s mission over 

the next five years. Through this 

Request for Information, NIAAA seeks 

comments on the draft outline for its FY 

2022–2026 Strategic Plan from diverse 

stakeholders, including scientific 

experts, health care providers, patients 

and family members, advocacy groups, 

other federal agencies, and nongovernmental scientific, professional, 

and healthcare organizations. 

DATES: Comments must be received by 

July 30, 2021, to ensure consideration. 

Responses will be reviewed by NIAAA 

staff and considered during the 

development of the 2022–2026 Strategic 

Plan. 

ADDRESSES: To view and comment on 

the strategic plan outline, please visit 

our online response form: RFI online 

response form. 

FOR FURTHER INFORMATION CONTACT: 

Rachel I. Anderson, Strategic Plan 

Coordinator, Office of Science Policy 

and Communications, National Institute 

on Alcohol Abuse and Alcoholism, NIH, 

6700B Rockledge Drive, Bethesda, MD 

20817. Telephone: 301–827–4681. 

Email: NIAAASciencePolicyBranch@

nih.gov. 

SUPPLEMENTARY INFORMATION: In 

accordance with the 21st Century Cures 

Act, NIH institutes are required to 

regularly update their strategic plans. 

The mission of the National Institute on 

Alcohol Abuse and Alcoholism 

(NIAAA) is to generate and disseminate 

fundamental knowledge about the 

effects of alcohol on health and wellbeing, and apply that knowledge to 

improve diagnosis, prevention, and 

treatment of alcohol-related problems, 


khammond on DSKJM1Z7X2PROD with NOTICES
Federal Register / Vol. 86, No. 119 / Thursday, June 24, 2021 / Notices 33325 

including alcohol use disorder, across 

the lifespan. NIAAA is the world’s 

largest funder of alcohol research. 

Dated: June 16, 2021. 

Vicki E. Buckley, 

Associate Director of Administration, 

National Institute on Alcohol Abuse and 

Alcoholism, National Institutes of Health. 

[FR Doc. 2021–13239 Filed 6–23–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; New Technologies for the In 

Vivo Delivery of Gene Therapeutics for an 

HIV Cure (R01 Clinical Trial Not Allowed). 

Date: July 16, 2021. 

Time: 10:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 3G22B, 

Rockville, MD 20892, (Virtual Meeting). 

Contact Person: Kristina S. Wickham, 

Ph.D., Scientific Review Officer, Scientific 

Review Program, Division of Extramural 

Activities, National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 3G22B, 

Rockville, MD 20852, 301–761–5390, 

kristina.wickham@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: June 17, 2021. 

Tyeshia M. Roberson, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–13219 Filed 6–23–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Neurological 

Disorders and Stroke; Notice of Closed 

Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Neurological Disorders and Stroke Special 

Emphasis Panel; Clinical Trials in Neurology. 

Date: July 12–13, 2021. 

Time: 9:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Virtual 

Meeting). 

Contact Person: Shanta Rajaram, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, Division of Extramural Activities, 

NINDS/NIH, NSC, 6001 Executive Blvd., 

Suite 3208, MSC 9529, Rockville, MD 20852, 

(301) 435–6033, rajarams@mail.nih.gov. 

Name of Committee: National Institute of 

Neurological Disorders and Stroke Special 

Emphasis Panel; P01 Review. 

Date: July 19–23, 2021. 

Time: 9:00 a.m. to 2:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Virtual 

Meeting). 

Contact Person: Li Jia, Ph.D., Scientific 

Review Officer, Scientific Review Branch, 

Division of Extramural Research, NINDS/ 

NIH, 6001 Executive Boulevard, Room 

3208D, Rockville, MD 20852, 301 451–2854, 

li.jia@nih.gov. 

Name of Committee: National Institute of 

Neurological Disorders and Stroke Special 

Emphasis Panel; Initial Translation Efforts for 

Non-Addictive Analgesic Therapeutics 

Development. 

Date: July 21–22, 2021. 

Time: 9:30 a.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Virtual 

Meeting). 

Contact Person: Diana M. Cummings, 

Ph.D., Scientific Review Officer, Scientific 

Review Branch, National Institute of 

Neurological Disorders and Stroke, NIH, 

NSC, 6001 Executive Blvd., Suite 3208, 

Rockville, MD 20852, cummingsdi@

ninds.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.853, Clinical Research 

Related to Neurological Disorders; 93.854, 

Biological Basis Research in the 

Neurosciences, National Institutes of Health, 

HHS) 

Dated: June 15, 2021. 

Tyeshia M. Roberson, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–13347 Filed 6–23–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Eunice Kennedy Shriver National 

Institute of Child Health & Human 

Development; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Child Health and Human Development Initial 

Review Group Developmental Biology Study 

Section. 

Date: June 25, 2021. 

Time: 9:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Eunice Kennedy Shriver National 

Institute of Child Health and Human 

Development, NIH, 6710B Rockledge Drive, 

2121D, Bethesda, MD 20817, (Virtual 

Meeting). 

Contact Person: Cathy J. Wedeen, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, Eunice Kennedy Shriver National 

Institute of Child Health and Human 

Development, NIH, 6710B Rockledge Drive, 

Room 2121D, Bethesda, MD 20892–7510, 

(301) 435–6878, cathy.wedeen@nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 


khammond on DSKJM1Z7X2PROD with NOTICES